Ann: Veyonda FDA Approved Trial to Commence, page-14

Strange attitude @harvett. I can't imagine there is strategy behind this downramping so I assume it's personal from the Novogen days? Don't let that cloud your investing. This is still a life-changing entry price - take a position!

Do you seriously think they could not get funding and approval for a Phase 2/3 in a heartbeat if they wanted to? It's actually a completely rational and deliberate strategy to hit multiple phase 1/2s across the various combinations. NOX could afford maybe one reasonably sized phase 2 trial without serious dilution, and then if successful, would seriously undervalue Veyonda.